Glycomics, the study of individual glycomes, is a critical field that holds potential for disease diagnosis, cancer detection, and precision immunotherapy. Denong Wang, the Senior Program Director of SRI Biosciences’ Tumor Glycomics Laboratory, and his team focus on exploring the diversity of glycomes to identify sugar chain signatures of microbes and cancers.
In his recent publication in ELISA, Wang presents protocols for detecting immunologically potent carbohydrates and discusses strategies to identify promising targets for therapeutics. This publication aims to provide practical assay protocols for scientists to identify and characterize sugar chain signatures that are clinically significant, such as those found in cancer cells and pathogens.
Importance for the Scientific Community
This publication is important for the scientific community as it enables scientists from various fields to characterize immunologically potent targets related to diseases and cancers. By sharing these protocols, it creates a wider network of researchers working towards improving the health and wellness of those impacted by these diseases.
Effective Identification of Microbes and Tumors
Wang’s team utilizes multiple assay platforms to effectively identify sugar chain targets. They employ techniques such as carbohydrate microarrays or glycan arrays to screen for specific targets pertaining to pathogens or tumors. Verification of pathogen or tumor-expression of these sugar signatures is done using other assays like glycan-specific enzyme-linked immunosorbent assay (ELISA), flow cytometry, and Fiber-optic Array Scanning Technology (FAST-scan).
SRI’s Role in Glycomics Research
SRI has played a significant role in the development of glycomics research. Their team, along with other researchers, has put in dedicated efforts to develop tools for studying carbohydrates and sugar chain signatures. Their carbohydrate microarray platforms have proved to be powerful means for probing sugar chain signatures, which has broad implications for biomedical use. SRI continues to advance glycomics research to address challenging issues such as the development of broad-spectrum antiviral agents to enhance pandemic preparedness and exploration of tumor glycan markers to advance precision immunotherapy.
More information: Denong Wang, Assessment of Immunologically Potent Carbohydrates, ELISA (2023). DOI: 10.1007/978-1-0716-2903-1_10
Citation: Q&A: Scientist shares glycomics protocols with the scientific community (2023, June 20) retrieved 20 June 2023 from https://phys.org/news/2023-06-qa-scientist-glycomics-protocols-scientific.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without written permission. The content is provided for informational purposes only.
Denial of responsibility! TechCodex is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
Jessica Irvine is a tech enthusiast specializing in gadgets. From smart home devices to cutting-edge electronics, Jessica explores the world of consumer tech, offering readers comprehensive reviews, hands-on experiences, and expert insights into the coolest and most innovative gadgets on the market.
